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Solid  lipid  nanoparticles  incorporating  Curcuma  longa  L., Zingiberaceae,  curcuminoids  were  produced  by
the hot  melt  emulsion  method.  A Box–Behnken  factorial  design  was  adopted  to study  the  nanoparticles
production  at different  levels  of  factors  such  as the  percentage  of curcuminoids,  time  of homogeniza-
tion  and  surfactant  ratio.  The  optimized  nanoparticles  were  incorporated  into  hydrogels  for  stability,
drug  release  and  skin permeation  tests.  The  average  nanoparticle  sizes  were 210.4  nm; the  zeta  poten-
tial  of  −30.40  ± 4.16;  the polydispersivity  was  0.222  ±  0.125.  The  average  encapsulation  efﬁciency  of
curcumin  and  curcuminoids  was  52.92  ± 5.41%  and  48.39  ±  6.62%,  respectively.  Solid lipid  nanocapsules
were  obtained  with  curcumin  load  varying  from  14.2  to 33.6%  and  total  curcuminoids  load  as  high  as
47.7%.  The  topical  formulation  containing  SLN-Curcuminoids  showed  good  spreadability  and  stability
when  subjected  to mechanical  stress  test  remained  with  characteristic  color,  showed  no phase  separa-
tion  and  no  signiﬁcant  change  in pH.  As a result  of slow  release,  the  nanoparticles  were  able  to  avoid
permeation  or penetration  in  the  pig  ear  epidermis/dermis  during  18  h.  The  topical  formulation  is sta-
ble  and can  be used  in  further  in  vivo studies  for the  treatment  of inﬂammatory  reactions,  in  special  for
radiodermitis.
© 2014 Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
In the last decade the curcuminoids from Curcuma longa L., Zin-
iberaceae, were reported in several molecular signaling pathways
f clinical importance (Goel et al., 2008; Das et al., 2010; Mourtas
t al., 2011). They have anti-inﬂammatory, antifungal, antimicro-
ial, antioxidant and antiproliferative properties (Aggarwal and
arikumar, 2009; Augustyniak et al., 2010; Irving et al., 2011; Zhou
t al., 2011), among others. The main curcuminoids from Curcuma
re curcumin, desmethoxycurcumin and bisdesmethoxycurcumin,
hree bioactive substances commonly used as spices and coloring
gents in food. However, these molecules have poor bioactivity and
nstability in neutral and alkaline aqueous solutions (Tønnesen and
arlsen, 1985; Yallapu et al., 2012) and hydrophilic topical formula-
ions. Besides, when curcuminoids were subjected to light exposure
here was 30% degradation and 1.8% loss under oxygen action in 30
ays. Despite their several utilities and low toxicity (Jayaprakasha
t al., 2006), the curcuminoids low bioavailability (Gao et al., 2011)
∗ Corresponding author.
E-mail: lapfrei@fcfrp.usp.br (L.A.P. Freitas).
http://dx.doi.org/10.1016/j.bjp.2014.11.010
102-695X/© 2014 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editoracontributes to recent growth of interest in developing new carrier
systems (Nair et al., 2010).
Due to anatomical and physiological characteristics of the skin,
some ingredients may  not acquire the desired activity topically and
new drug carrier systems have been used to modify the perme-
ation/penetration. According to Mehnert and Mader (2001), it is
becoming evident that the development of a single drug is no longer
sufﬁcient for the evolution of therapy, given the insufﬁcient con-
centration of the drug due to its low absorption, rapid metabolism
and elimination; high toxicity in combination with other fabrics
and high ﬂuctuation in plasma levels due to unpredictable bioavail-
ability after perioral administration.
Lipid-based nanoparticle systems are commonly used in topi-
cal applications (Contri et al., 2011) and are prepared with solid
structures at room temperature or at body temperature associated
with surface-active agents and water lipids. According to Oliveira
(2008), lipophilic drugs will have an easier penetration, given the
characteristics of the plasma membrane. In this regard, skin per-
meation enhancing agents can be used in the formulations and can
reduce skin resistance (Martins and Veiga, 2002).
Over the past 10 years solid lipid nanoparticles (SLN) and
nanostructured lipid carriers (NLC) through mixtures of lipids that
 Ltda. All rights reserved.
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cquire a speciﬁc molecular arrangement were produced, suf-
ering a major effect of surfactants added to these formulations
Serra et al., 2009). This combination of surfactants is considered to
mprove stability by preventing agglomeration of the particles and
etarding the time of polymorphic transition of lipids to encapsu-
ate the active ingredient (Serra et al., 2009).
Hydrophilic matrix systems are commonly used due to low
roduction costs, acceptance by regulatory organ, simplicity of for-
ulation, production facility, capacity to incorporate a range of
ubstances with extended solubility range (Lyra et al., 2007), and in
eneral, have a thixotropic or pseudoplastic rheological behavior,
uring application becoming more ﬂuid, facilitating the spreading
nd recovering the initial viscosity upon ending the application,
hich prevents the product drips (Martin, 1993). These products
ends to have a longer shelf life, because during storage (dur-
ng which time the product remains at rest), presents constant
iscosity, which makes difﬁcult to separating the formulation con-
tituents.
Hydrophilic gels have been demonstrated to be adequate for
ncorporation of SLN (Jenning et al., 2000). By reducing trans-
pidermal loss of water and improving skin hydration, an increase
n penetration and percutaneous absorption has been reported
Jenning et al., 2000; Wissing et al., 2001). Other advantage of this
ystem is to promote the controlled release of substances, reduc-
ng their systemic absorption and acting as a physical sunscreen
Attama and Muller-Goymann, 2008). These properties are of great
mportance for the protection of skin from patients undergoing
adiotherapy treatment.
The aim of this research was to develop solid lipid nanoparticles
SLN) containing curcuminoids using a natural wax  as encapsu-
ating matrix and to develop and characterize a hydrophilic gel,
or topical application. The nanoparticle preparation was studied
pplying a Box–Behnken design and the hydro gel stability and ex
ivo skin curcuminoid permeation/penetration was evaluated.
aterials and methods
lant and other materials
The curcuminoid concentrate was purchased from CHR (Chris-
ian Hansen A/S, Denmark) and pharmacognostically characterized,
nd a sample counterproof was deposited at the “Herboteca LADI-
ARP” from the FCFRP/USP with Registry number CP01/14-S. The
owder moisture content, total ash content, swelling index and
ize distribution were determined according to the methodolo-
ies described in Farmacopeia Brasileira (2010). The results were
xpressed as mean ± standard deviation of three replicates. Analyt-
cal grade curcumin as a standard for quantiﬁcation purpose was
urchased from Sigma (Sigma–Aldrich, St. Louis, MO,  USA).
uantiﬁcation of curcumin and curcuminoids
For curcumin and total curcuminoid content determination a
PLC method was developed. Brieﬂy, an Ultimate 3000 (Thermo
isher Brasil Ltda, São Paulo, Brazil) HPLC was used with a C18
lcrom column (Phenomenex Ltda, São Paulo, Brazil). The mobile
hase was 50:50 acetonitrile and acidiﬁed water (1% citric acid) at
H 3.5, ﬂow rate of 1.0 ml/min. The UV–vis detector was  set up to
25 nm.  50 l samples were injected (Paulucci et al., 2013).
The curcumin standard (Sigma–Aldrich, St. Louis, USA) solu-
ion was prepared with 1 mg  of curcumin in 5 ml  of 50:50
cetronitrile:water (1% citric acid). Consecutive dilutions were
ade to obtain seven solutions at concentrations from 25 to
500 ng/ml, which were injected to prepare the analytical curve.
he method linearity and selectivity were also evaluated. Samplese Farmacognosia 25 (2015) 53–60
of drug (curcuminoids), unloaded nanocapsules, curcumin loaded
nanocapsules, pig ear extract, hydrophilic gel, and gel containing
nanocapsules were tested for selectivity.
Preparation of solid lipid nanoparticles SLN
SLN were prepared by hot melt emulsion technique (Martins,
2014; Zamarioli, 2014) employing a high-shear homogenizer.
Brieﬂy, water was heated at 70 ◦C with Tween 80 (polyethylene gly-
col sorbitan monooleate) and lecithin (phosphatidylcholine), prior
to addition of the oily phase. The beeswax and curcuminoids were
heated and homogenized at same temperature. The microemulsion
was produced by dropping the oily phase in aqueous solution with
the aid of a glass syringe. The dispersion was submitted to high shear
homogenization at 70 ◦C using an Ultra-Turrax T25 (IKA®, Wilming-
ton, USA) at 20,000 rpm during 20 min. The lipid nanoparticles were
solidiﬁed by cooling down the dispersion. All experiments were
kept in an ice bath with magnetic stirring after homogenization for
10 min.
Factorial design
The SLN production was studied using a Box–Behnken factorial
design (Boax et al., 1978) for three factors at three levels, result-
ing in ﬁfteen experiments. Table 1 shows the studied factors and
the ranges of each one: the percentage of curcuminoids in beeswax
nanoparticles, %C:Bw; the homogenization time using Turrax, HT
and the weight proportion of lecithin to Tween 80, L:T. The choices
of the ranges of the factors shown in Table 1 were based on prelim-
inary experiments and the range of proportion of lecithin to Tween
80 was  based on the hydrophilic–lipophilic balance (HLB).
Characterization of SLN
The particle size (Dp) distribution and polydispersivity index
(PdI) were obtained by photon spectroscopy (PCS) employing
a Zetasizer Nano Series (Malvern Instruments Limited, Worcs,
UK). Zeta potential was  assessed by determining the particle
electrophoretic mobility using the same apparatus. These mea-
surements were performed at 25 ◦C using water as the dispersing
medium and dilution of suspensions of nanoparticles at a ratio of
1:100 in ultrapure water (Milli Q, Millipore Inc., USA).
Morphology
The surface appearance and shape of SLN were determined by
an atomic force microscope (AFM) model SPM-9600 (Shimadzu Co.,
Kyoto, Japan). The dispersion of SLN was  diluted (1:100) using ultra-
pure water (Milli-Q, Millipore Inc., USA) and spread onto thin mica
plates.
Encapsulation efﬁciency and drug load
Aliquots of 1.5 ml  of the SLN dispersions were placed in
Eppendorf and subjected to centrifugation in a HT – MCD  2000
(Biosystems Ltd., Curitiba, Brazil) at 9300 × g for 20 min; the
supernatant was extracted, ﬁltered in 45 M ﬁlter (Millipore Inc.,
USA) and stored in vials for further HPLC quantiﬁcation. In each
Eppendorf 1.5 ml  of Milli-Q water was  added to the remaining
precipitated material. This solution was subject to new cycles of
centrifugation and supernatant collection under the same con-
ditions. The supernatant became colorless after three extraction
cycles. The curcumin or curcuminoid content in the three super-
natant samples was  quantiﬁed by HPLC and was assumed as being
outside the SLN, or non-encapsulated. 1.5 ml  of ethanol 70◦GL was
added to the precipitate obtained after the third centrifugation. The
solution was sonicated for 60 min  in ultrasound bath and thereafter
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Table  1
Levels and codiﬁcation of variables studied.
Factors Level (−1) Level (0) Level (+1)
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rX1 – percentage of curcuminoids/beeswax 5% 
X2 – time in Turrax* in min 10 
X3 – proportion of Lecithin/Tween 80 0.5 
o a cycle of centrifugation at 9300 × g for 20 min. The super-
atant was aspirated, ﬁltered and placed in vials for curcumin and
urcuminoid quantiﬁcation. The latter were considered to be the
urcuminoids that were encapsulated in the SLN. The encapsulation
fﬁciency, %EE, was calculated by Eq. (1).
EE = (CC/CT + CC) × 100 (1)
here CEnc is the amount of curcuminoids inside the SLN and CT
s the total amount of curcuminoids added to the formulation.
reparation of topical formulation
In order to contemplate the objective of this project, we chose to
repare a known base formulation, the gel Natrosol® (Via Pharma
tda, São Paulo, Brazil) at a concentration of 1.5%. The incorporation
f SLN dispersions into gel components was performed at room
emperature, as beeswax becomes softened at around 50 ◦C.
n vitro release proﬁle
Brieﬂy, an aliquot of 20 l of the SLN dispersion correspond-
ng to 59.2 mg  of curcuminoids was dispersed in phosphate buffer,
istributed in ﬁve tubes and kept at room temperature. At the
redetermined intervals, the tubes were centrifuged at 200 × g for
 min  (Bisht et al., 2007) to separate the curcuminoids crystals pre-
ipitated after release from SLN. After centrifugation, the dispersion
as aspirated and placed into new tubes for subsequent centrifu-
ation, and again the curcuminoid remaining crystals dissolved in
 ml  of methanol. This volume was ﬁltered (0.45 M)  and analyzed
n HPLC for quantiﬁcation.
x vivo permeation study
The permeation tests were performed using Franz cell diffu-
ion (1.77 cm2 of area) with pig ear skin. The pig ear skin was
btained from slaughterhouse overseen by the Ministry of Agri-
ulture, located in the municipality of Ipuã (Olhos D’Água Indústria
 Comércio de Carnes Ltda, Ipuã, SP, Brasil).
The experiments were performed with six cells: (1) one cell
or the control group with curcuminoids solution; (2) two cells
ith Natrosol gel containing curcuminoids and (3) three cells with
he gel containing nanoencapsulated curcuminoids (0.5 g of gel in
ach). For the receptor solution 0.2 M phosphate buffer was  used
ith 20% ethanol (Suwantong et al., 2007), pH 7.5, maintained at
7 ± 0.5 ◦C in thermostatic bath with continuous stirring for 18 h.
amples were withdrawn from the receptor compartment after 0,
5, 30 and 60 min  and at 2, 4, 6, 8, 10, 12, 14, 16 and 18 h of assay
nd immediately quantiﬁed by HPLC.
After the 18 h, the skin was removed from Franz apparatus,
ried with a ﬁne cloth and repetitive (n = 15) removal of the
tratum corneum was performed with adhesive tape (3 M,  Sumaré,
ão Paulo, Brazil) 19 mm × 50 m.  The tapes were placed in Falcon
ubes (50 ml)  containing 0.2 M phosphate buffer with 20% ethanol
Suwantong et al., 2007), agitated in a vortex model AT 56 (Phoenix)
or 3 min, ﬁltered through a 0.45 M membrane (Millipore Corpo-
ation, Billerica, MA,  USA) and quantiﬁed in HPLC.10% 15%
15 20
1.0 1.5
Retention in the epidermis and dermis
The epidermis and dermis were minced and placed in Falcon
tube (50 ml)  containing 0.2 M phosphate buffer with 20% ethanol
(Suwantong et al., 2007), subjected to high shear agitation (Turrax)
at 3000 rpm for 1 min; sonicated in an ultrasound bath Model USC
1400 (Ultrasonic Cleaner) for 30 min  and centrifuged for 10 min  at
2790 × g in a centrifuge model HT – MCD  2000 (Biosystems Ltd.,
Curitiba, Brazil). The solution obtained was ﬁltered (0.45 M)  and
quantiﬁed in HPLC.
Stability of gel formulation with SLN
Preliminarily, the Natrosol® gel containing SLN-Cur was sub-
mitted to centrifugation at 2790 × g for 30 min (Anvisa, 2004).
Following, the formulation was  subjected to thermal stress cycles
alternating 24 h in the oven at 40 ± 2 ◦C and 24 h in the refrigerator
at 5 ± 2 ◦C. At the end of each cycle, organoleptic and physico-
chemical characteristics of the gel were evaluated. The pH of the
samples was obtained using a DM 20 pHmeter (Digimed, São Paulo,
SP, Brazil). This study was performed in six complete cycles. Also,
organoleptic and pH evaluation of gel containing the SLN-Cur was
performed after three months of storage. Samples were kept at two
test temperatures (25 ± 2 ◦C and 5 ± 2 ◦C) both in the absence and
presence of light.
Statistics
To examine this plan Minitab 16 software (Minitab Inc., State
College, PA) was  used, with its features of descriptive statistics,
experimental design (DOE) and response surface; to generate the
response surface graphs, Statistica version 12 (StatSoft, South
America, São Caetano do Sul, São Paulo, Brazil) was  used. Descrip-
tive analyses were mean, standard deviation, minimum, and
maximum. Conﬁdence interval was established for the analysis of
the release proﬁle of curcuminoids from SLN taken and variance
analysis in all experimental designs, with p < 0.05.
Results and discussion
The drug raw material was characterized according to
Farmacopeia Brasileira (2010) with all assays made in triplicate.
The total ash content was 0.10 ± 0.01%, and moisture content was
0.75 ± 0.02%. Mean particle size D50 was 30.8 m,  while D10 and
D90 were 13.7 and 168.2 m,  respectively. Size distribution span
was 0.20. The contents of curcumin, demethoxycurcumin and bis-
demethoxycurcumin in the drug were determined by HPLC using
the curcumin standard from Sigma and showed to be 76.7, 19.4 and
3.9%, respectively.
The HPLC method developed showed to be selective for cur-
cuminoids in samples of nanocapsules containing curcuminoids
and pig ear skin used in penetration/permeation assays. The chro-
matograms for curcumin analytical standard (Sigma–Aldrich, St.
Louis, USA), drug containing the three curcuminoids used as raw
material in this work and a sample extracted from pig skin after
penetration/permeation test are shown in Fig. 1A–C, respectively.
The analytical curve showed a squared correlation coefﬁcient, R2,
of 0.999.
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2Sigma–Aldrich); (B) drug containing the three curcuminoids used as raw
aterial; (C) sample extracted from pig skin after penetration/permeation test.
The Box–Behnken design was idealized after a series of previous
xperiments, varying the concentrations of beeswax, curcumi-
oids, surfactants, temperature, duration of shearing, mode of
urcuminoid addition and others. The results showed that the
LB (hydrophilic/lipophillic balance) is very important during the
anocapsules preparation and was considered in the further work.
he Box–Behnken design applied can be seen in Table 1, which
hows the factors studied and their levels. The results of nanoparti-
le sizes, polydispersivity (PdI) and zeta potential for all the ﬁfteen
xperimental conditions are shown in Table 2. As can be seen in
able 2, the PdI varied widely from 0.128 to 1.000. High values of PdI
ay  interfere with the reliability of the estimated size of particles
Zetasizer, 2009). The Malvern Zetasizer (2009) software applies
he cumulative analysis method, and calculates the zeta-average
size) and polydispersivity from the coefﬁcients of the virial equa-
ion. When cumulative analysis is not applicable, the PdI values are
bove 0.100 and neither zeta-average nor PdI values are reliable.
ased on this, the diameters were extracted directly from the fre-
uency distribution of sizes, i.e.,  from the center value of the peak
ith higher intensity.
Three examples of the size distributions can be seen in Fig. 2.
ig. 2A presents the signal intensity distribution for experiment 2
rom Table 1, where the SLN was prepared with 15% of curcum-
noids, 20 min  at high shear homogenizer and ratio of lecithin to
ween 80 equal to 1.0. As shown in this plot, there is only one peak
ith a reasonable narrow distribution and sizes varying from 100 to
00 nm.  Depending on the conditions of preparation the proﬁle ofe Farmacognosia 25 (2015) 53–60
the distribution can change considerably, as seen in Fig. 2B, which
shows the size distribution for experiment 5 from Table 1. In this
processing condition there are two well deﬁned peaks, or a bimodal
distribution: the ﬁrst peak with size from 20 to 80 nm and the sec-
ond and larger peak with size from 100 to 600 nm. In this condition,
there is also a very small peak appearing at sizes above 7000 nm.
Fig. 2C shows a third interesting result in a unimodal distribution
showing sizes from 150 to 550 nm (experiment 11 in Table 1). These
three plots are very illustrative of the strong effect of experimental
conditions on the nanoparticles size distributions, and the impor-
tance of using multivariate tools for effects elucidation. Since our
analysis must be based on the intensity distribution, only the largest
peaks were taken into consideration for mean size determination
at the situations where there are two or more peaks.
The values of mean sizes, polydispersivity and zeta potential for
all ﬁfteen experiments are shown in Table 2. Considering all exper-
iments in Table 2, an averaged particle size was 210.4 ± 146.6 nm,
with minimum and maximum of 32.7 nm and 481.9 nm,  respec-
tively. The averaged zeta potential was −29.0 ± 4.2 mV, varying
from a minimum of -35.3 mV  to a maximum of −21.2 mV.  The
averaged PdI was 0.546 ± 0.300, with a maximum of 1.000 and
minimum of the 0.128, but one must remember that this PdI was
calculated by Malvern cumulative analysis and can only be used
for qualitative purposes (Zetasizer, 2009) and not for quantitative
comparison.
The analysis of variance, ANOVA, by response surface methodol-
ogy resulted in a few signiﬁcant effects of the factors studied on Dp,
PdI and ZP. The Pareto plots in Fig. 3 bring the probabilities p for all
the linear, quadratic and interaction effects for the Box–Behnken
designs. Fig. 3A shows the Pareto plot for Dp, which indicates that
only the linear effect of the ratio of lecithin/Tween, L:T was  sig-
niﬁcant to SLN sizes at 5% (p < 0.05). The other factors and their
interactions were not signiﬁcant within the conﬁdence interval of
95%. The polynomial equation to ﬁt the surface response has only
X3 as a variable, as presented in Eq. (1).
Dp = 144.5 + 143.6(X3) (1)
The effect of surfactants ratio, L:T, on Dp was the unique signif-
icance in curcuminoids/beeswax SLN. Other authors (yet for Jebors
et al., 2010) reported no inﬂuence of agitation speed on the parti-
cle size, as observed in this work, and this can be attributed to the
thermodynamic effect of surfactant addition as being primordial
in emulsion formation. Besides, the use of small glassware in the
lab scale is commonly associated to strong wall effects, which may
cause the multimodal size distributions, which was observed in
Fig. 2B, and four other experimental conditions in this work. A com-
mon  practice is to ﬁlter the samples to cut off undesired sizes using
0.22 and 0.45 mm ﬁlters. In this work, however, the decision for no
ﬁltration aimed to study the actual implications of the method of
production and the real interference of the factors analyzed.
For the PdI only the linear effects of %C:Bw (X1) and L:T (X3) were
signiﬁcant at the adopted signiﬁcance level (p < 0.05). The other
factors were not signiﬁcant within the conﬁdence interval of 95%,
so they were not kept in the polynomial ﬁtting presented in Eq. (2).
PdI = 0.398 + 0.201(X1) − 0.309(X3) (2)
The changes in lecithin concentration when L:T is varied may be
related to increased polydispersity of the particles, since there is a
possible formation of multiple layers of lecithin on the surface of
the SLN or the formation of other colloidal structures (Jebors et al.,
2010).
Fig. 3B shows that for zeta potential, ZP, only the linear effect
of homogenization time (X2) and the quadratic effect of the ratio
of L:T (X3) were signiﬁcant. The other factors were not signiﬁcant
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Table  2
Size, PdI and zeta potential of SLN-Cur.
Exp. % Curcuminoids/beeswax Time in Turrax Proportion lecithin/Tween 80 Size (nm) Peak intensity (%) PdI Zeta (mV)
1 5 20 1.0 405.5 95.1 0.429 −21.2
2  15 20 1.0 128.9 100.0 0.627 −21.4
3  5 10 1.0 201.2 91.5 0.373 −28.7
4  15 10 1.0 62.2 100.0 1.000 −33.4
5  5 15 0.5 247.6 82.7 0.543 −33.3
6  15 15 0.5 45.0 100.0 1.000 −31.3
7  5 15 1.5 374.9 100.0 0.179 −28.9
8  15 15 1.5 481.9 100.0 0.504 −27.1
9  10 20 0.5 32.7 100.0 1.000 −29.1
10  10 10 0.5 62.4 100.0 0.972 −34.0
11  10 20 1.5 297.0 99.0 0.236 −28.0
12  10 10 1.5 382.9 100.0 0.128 −35.3
13  10 15 1.0 159.4 100.0 0.461 −29.3
14  10 15 1.0 150.2 100.0 0.361 −25.0
15  10 15 1.0 123.9 100.0 0.371 −29.1
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ithin the conﬁdence interval of 95%, so they were not kept in the
olynomial ﬁt presented in equation,
P = −27.80 + 3.96(X2) − 3.89(X3)2 (3)
The magnitude of the ZP can be associated with the ratio
f lecithin used in the formulations and interaction with other
omponents such as the Tween, which is a non-ionic surfac-
ant.
ncapsulation efﬁciency
The encapsulation efﬁciency, EE, varied from 41.4 to 62.0% for
urcumin and from 31.0 to 58.78% for total curcuminoids. The aver-
ged curcumin encapsulation efﬁciency for the ﬁfteen experiments
as 52.92 ± 5.41% and for total curcuminoids, 48.39 ± 6.62%. The
NOVA by response surface methodology showed that only %C:Bw
ffected EE at the signiﬁcance level of 5%. Fig. 4 shows the contour
lot of curcumin encapsulation efﬁciency in beeswax nanoparticles
s a function of homogenization time, HT, and percent curcumin
A P<0.05
HT x L:T
HT x HT
L:T x L:T
HT x C:Bw
C:Bw x C:Bw
C:Bw x L:T
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Fig. 3. Pareto diagrams showing the signiﬁcance of factors, HT, C:Bw and L:T,nm)
 experiments 2, 5 and 11 (A–C).
content, %C:Bw. Although literature data (Yallapu et al., 2013) indi-
cate that curcumin encapsulation can be higher for other carriers,
EE above 50% may  be considered good for a lipophilic drug and the
EE varies strongly depending on different systems and processes.
A polynomial equation was ﬁtted to the date of %EE for curcumin
and is given in Eq. (4).
%EE = 53.30 + 5.60(X1) (4)
Morphological analysis
Fig. 5 shows the morphology of the SLN by atomic force
microscopy, AFM. Fig. 5A presents the topographic view, while
the frontal view is shown in Fig. 5B. It was  evident that particles
were spherical in shape and homogeneously distributed with size
ranged between 52 nm and 101 nm,  smaller than that measured by
dynamic light scattering.
B
P<0.05
HT x L:T
HT x HT
L:T x L:T
HT x C:Bw
C:Bw x C:Bw
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0.042
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0.972
*
*
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HT
ability, p
 for particle size (A) and zeta potential (2B). *Signiﬁcant at 5% (p < 0.05).
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Fig. 6. Curcuminoid release in phosphate buffer (pH 7.4) solution after 16-h test.
Experiments made in sextuplicate.
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 (-
)
Cycles (48 h)
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1.0
2.0
3.0
4.0
5.0
6.0ig. 4. Contour plot of encapsulation efﬁciency, EE%, of curcumin in beeswax
anoparticles as a function of homogenization time, HT, and percent curcumin
ontent, %C:Bw. Only the effect of %C:Bw is signiﬁcant at p < 0.05.
elease proﬁle
All the samples of nanocapsules tested showed a sustained but
ot linear release (Fig. 6), as seen in the literature as a ﬁrst order
inetics (Nayak et al., 2010; Puglia et al., 2012). Approximately
0–60% of curcumin was released after 2 h of experiment. How-
ver, around 40% of curcuminoids remained unreleased after 10 h
f experiment. Nayak et al. (2010) found, using the same method-
logy, that after 12 h of experiment 70% of curcuminoids had been
eleased, and within 24 h of release was around 80%. The extended-
elease proﬁle may  indicate interactions between the lipid and the
rug and a more central location of this drug in the SLN (Küchler
t al., 2009), beyond the inﬂuence of the surfactants used.
reliminary stability
The formulation did not undergo phase separation when sub-
ected to mechanical stress test by centrifugation (Anvisa, 2004).
he gel remained homogeneous, with bright and light yellow color,
haracteristic odor and no phase separation during the mechanical
tress at 3000 rpm for 30 min. Fig. 7 shows the pH values measured
t the end of each thermal stress cycle of 24 h at 40 ◦C and 24 h at
◦C. The pH remained pretty stable over the test period (Fig. 8) andt has undergone minor changes that were not signiﬁcantly differ-
nt than the pH of the gel initially made. The pH of the gel, slightly
elow 6.0, is physiologically adequate for topical use and also ade-
uate for chemical stability, since curcuminoids are unstable at pH
A 
1.00
1.00
0.50
0.50
0.00
Fig. 5. Atomic force microscopy. TopoFig. 7. pH of hydrogel containing the curcumin SLN based on pH values after six
48  h stress cycles of heating (40 ◦C for 24 h) and cooling (5 ◦C for 24 h).
above 7 (Tønnesen and Karlsen, 1985; Rusig and Martins, 1992).
Another stability test was run for 90 days, with gel samples stored
at test temperatures of 25 ± 2 ◦C and 5 ± 2 ◦C, in the absence or pres-
ence of light. The organoleptic evaluation of the gel showed no
signiﬁcant changes in appearances and no phase separation. The
pH of the gel containing the SLN-Cur did not change signiﬁcantly
after three months if compared to the beginning of the tests. The
pH was  5.48 for the gel kept at 25 ± 2 ◦C in absence of light, 5.13 for
the sample at the same temperature but under daylight and 5.66 for
the gel stored at 5 ± 2 ◦C. The centrifugation test was  also performed
and the three samples did not undergo phase separation.
Ex vivo penetration and permeation study
The HPLC analyses of extratum corneum and epidermis + dermis
after the 18 h experiments in Franz cells are shown in Figs. 8 and 9,
respectively. There was  no permeation of curcuminoids in pig ear
skin during any of the sixplicates, which indicate a controlled
release from SLN in gel with release time longer than 18 h. Due
B
graphic (A) and frontal view (B).
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o limitations imposed by the use of ex vivo biological material,
he permeation experiment cannot be longer than 18 h, since the
ig ear skin undergoes strong changes after this period at 37 ◦C
Sartorelli et al., 2000).
Penetration of curcumin or curcuminoids was not observed for
ny formulation in triplicate, e.g.,  gel containing the SLN-Cur and gel
ith free curcuminoids, which corroborates with the idea of very
low release from nanocapsules. The results corroborate the state-
ent that nanotechnology can modify the penetration/permeation
f substance and control their release, increasing the residence time
n the skin surface (Luengo et al., 2006; Guterres et al., 2007; Cevc
nd Vieri, 2010).
Since the goal of this work was to develop an anti-inﬂammatory
opical formulation for radiodermitis, it is adequate that curcumi-
oids show a slow release and that SLN-Cur does not penetrate in
ormal skin, behavior that can be signiﬁcantly changed in skin dam-
ged by radiotherapy buns. The result is stimulating and should be
onﬁrmed in future in vivo tests for normal and injured skin, since
enetration/permeation in vivo can be considerably different from
x vivo because of shear caused by body movement and also by
kin injures caused by radiation (radiodermitis), which may  favor
he penetration of curcuminoids.
onclusions
Beeswax showed to be an excellent natural carrier for cur-
uminoids nanoencapsulation, resulting in nanocapsules with
dequate size and zeta potential. Encapsulation efﬁciencies and
rug load in nanocapsules also demonstrate that the process devel-
ped is promising. The application of factorial design to studyeation tests. Aiming for quantiﬁcation of curcuminoids in epidermis and dermis.
sed to the gel with free curcuminoids and epidermis + dermis exposed to gel with
the preparation process for nanocapsules showed to be a very
important tool, allowing establishing the relationships among the
factors and quality attributes. Hydrophilic gel containing solid lipid
nanocapsules showed to be stable in preliminary tests and that pen-
etration/permeation in pig skin could not be detected in 18 h. Assay
in Franz cells using pig ear skin showed no penetration/permeation
of nanoencapsulated curcuminoids. The results are stimulating for
future in vivo tests of anti-inﬂammatory activity in radiodermitis
treatment.
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